Arthneeti
SA

Solara Active

Q1 FY27Pharmaceuticals & Biotechnology

Solara Active Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹632
Market cap₹2.9K Cr
P/E690.5
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueRank 3
MarginRank 3
CapexYes
Order bookYes

Not discussed on this call: fundraise.

The short version

The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15). The company expects around 10% year-on-year growth in the base business revenues, considered sustainable in the near term.

From Solara Active's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3
  • The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15).
  • Recent quarters show a new plateau with base business revenues crossing INR 300 crores, indicating a higher level of operations (Page 9).
  • Year-on-year growth for Q1 FY27 over Q1 FY26 was approximately 24%, and even after adjusting for pass-through cost inflation, growth was around 18-19% (Page 9).
  • Growth drivers include geographic expansion and debottlenecking capacity to increase volumes in high-margin products (Page 14).
  • Management is cautious about giving long-term (5-year) outlooks due to the dynamic external environment but expects to at least sustain or grow from the current levels (Page 14).
  • The ibuprofen business remains a commodity-driven segment with unpredictable dynamics; no specific strategic decision made yet (Pages 15-16).

Profitability & Margins

See what Solara Active said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes
  • For FY '27, Solara has committed to close to INR 55-60 crores of capex.
  • Around INR 40 crores of this is towards incremental debottlenecking capex to increase capacity for high-margin products.
  • The remaining INR 10-15 crores is for maintenance capex, including plant upgrades and equipment replacements.
  • Similar capex levels of INR 40-50 crores per year are planned for FY '28 and FY '29.
  • The focus is primarily on brownfield investments—debottlenecking existing lines rather than greenfield expansions.
  • Greenfield capex is currently not being actively considered, although the company remains open to opportunities as they evolve.
  • Vizag facility retrofit plans for CRAMS work are on hold pending strategic decisions expected by Q2 FY '27 results.
  • Overall, the strategy emphasizes maximizing output via operational efficiency and capacity enhancement rather than new plant builds.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Solara Active said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Yes
The provided transcript from Solara Active Pharma Sciences Limited's Q1 FY27 earnings call does not specifically mention the current or expected order book or pending orders. However, relevant insights include: - The company is focusing on expanding its existing base business and seeding new businesses. - The base business has shown strong momentum with revenues up 24% year-on-year. - There is ongoing geographic expansion and new business wins. - The company is actively manufacturing and selling around 40-50 products from a basket of 50-60 products. - They are working on debottlenecking capacity to increase volumes for high-margin products. - Management expresses confidence in sustaining or growing business revenue by at least 10% year-on-year. - No quantified order book or pending orders data is explicitly provided in the transcript. If exact order book details are needed, they may be available in a different section of the full report or through direct company disclosures.

Solara Active — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active Pharma Sciences Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Solara Active Q1 FY27 results?

The company targets a sustainable revenue growth of around 10% year-on-year for the base business (Page 14-15). The company expects around 10% year-on-year growth in the base business revenues, considered sustainable in the near term.

What is Solara Active share price analysis?

Solara Active currently shows a below-average growth signal. The stock trades at a P/E of 690.5 with a market cap of ₹2,948 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active planning capital expenditure?

For FY '27, Solara has committed to close to INR 55-60 crores of capex.

Keep Solara Active on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.